Skip to content

Ardelyx ARDX Gross Unrealized Gains

Gross Unrealized Gains at other companies

Amgen logo
AmgenAMGN
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO

Other financials

Income statement

See full
Revenue$94.5M+27.5%
Gross profit$89.7M+45.1%
Operating income-$32.8M+9.8%
Net income-$37.6M+8.6%
EPS (diluted)-$0.15+11.8%

Balance sheet

See full
Cash & equivalents$31.2M+1.3%
Total debt$208.3M+34.3%
Total equity$148.6M+2.0%
Total assets$504.5M+23.0%

Cash flow

See full
Operating cash flow-$32.2M+16.2%
CapEx$69.0K-78.8%
Free cash flow-$32.3M+16.7%

Valuation

See full
Market cap$1.5B+75.8%
Enterprise value$1.67B+71.5%
P/S3.5×+1.1×

Profitability

See full
Gross margin92.5%+7.9pp
Operating margin-25.4%
Net margin-13.6%
FCF margin-40.9%

Returns & leverage

See full
Return on equity-39.5%
Debt / equity1.4×+0.3×
Current ratio3.5×-0.6×

Where this comes from

Reported directly by Ardelyx in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.

The official record: Ardelyx’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ardelyx's gross unrealized gains.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ardelyx's gross unrealized gains?
Ardelyx (ARDX) reported gross unrealized gains of $22K in Q1 2026.
How has Ardelyx's gross unrealized gains changed year-over-year?
Ardelyx's gross unrealized gains decreased by 60.7% year-over-year, from $56K to $22K.
What is the long-term trend for Ardelyx's gross unrealized gains?
Over 5 years (2020 to 2025), Ardelyx's gross unrealized gains has grown at a 95.7% compound annual growth rate (CAGR), from $7K to $201K.